MRSA head and neck infections increase among children



A new analysis of the National Cancer Institute’s cancer registry has found that as many as one in five older women experience delayed or incomplete radiation treatment following breast-conserving surgery, and that this suboptimal care can lead to worse outcomes. Dr. Heather Taffet Gold of Weill Cornell Medical College and colleagues found that among

Full Post: Breast cancer increases with radiation delays

Rates of antibiotic-resistant head and neck infections increased in pediatric patients nationwide between 2001 and 2006, according to a report in the January issue of Archives of Otolaryngology-Head & Neck Surgery.

Before the 1980s, infections with strains of the bacteria Staphylococcus aureus resistant to the antibiotic methicillin (methicillin-resistant Staphylococcus aureus, or MRSA) were most often acquired in the hospital, according to background information in the article. However, during the past decade, community-acquired MRSA infections have become more common in prisons, nursing homes and among chronically ill patients and in individuals without established risk factors. ” Staphylococcus aureus is a pathogen commonly seen in many infections involving the head and neck,” the authors write. “In recent years, there have been increasing reports of community-acquired MRSA infections in children.”

Iman Naseri, M.D., of Emory University School of Medicine, Atlanta, and colleagues reviewed data regarding pediatric head and neck infections that occurred at more than 300 hospitals nationwide between 2001 and 2006. Sites of infection were divided into oropharyngeal/neck (head and neck), sinonasal (nose and sinuses) and otologic (ear), and demographic and antibiotic resistance patterns were reviewed.

Of 21,009 S. aureus infections that occurred during this period, 21.6 percent (4,534) were resistant to methicillin. MRSA rates increased from 11.8 percent in 2001 to 28.1 percent in 2006. “This represents a 16.3-percent increase in MRSA during these six years for all pediatric head and neck S. aureus infections,” the authors write.

Among the three groups of infection sites, the highest proportion of MRSA was found in the ears (34 percent), followed by the sinonasal (28.3 percent) and the head and neck (14.2 percent) groups. Regional differences were also found, which could be attributed to geographical disparities in the treatment of head and neck infections.

“Judicious use of antibiotic agents and increased effectiveness in diagnosis and treatment are warranted to reduce further antimicrobial drug resistance in pediatric head and neck infections,” the authors write.

“Expeditious culture of suspected head and neck infections leading to more appropriate antimicrobial drug selection is highly recommended to avoid further resistant patterns,” they conclude. “Further studies linking the microbiologic and clinical behaviors of MRSA are warranted to gain additional insight into the dynamic existence of this organism.”

http://archotol.ama-assn.org/

Link




Pre-operative screening of patients for methicillin-resistant Staphylococcus aureus (MRSA) may be an effective way to reduce infection rates following otolaryngic surgeries, according to new research published in the January 2009 issue of Otolaryngology - Head and Neck Surgery. The study, conducted by researchers at the Massachusetts Ear & Eye Infirmary, is the first to review otolaryngic

Full Post: MRSA pre-screening effective in reducing otolaryngic surgical infection rates



Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone. Ceftobiprole is licensed from and co-developed with Basilea Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in Switzerland under the trade name Zevtera.

Full Post: Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections



Targanta Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the November 19, 2008 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. AIDAC will review Targanta’s New Drug Application (NDA) for oritavancin for the treatment of complicated skin and skin structure infection (cSSSI) caused by gram-positive

Full Post: Targanta Therapeutics announces posting of briefing documents for review of FDA



An enzyme that lives in Methicillin-resistant Staphylococcus aureus (MRSA) and helps the dangerous bacterium to grow and spread infection through the human body has been visualised for the first time, according to a study out today in Proceedings of the National Academy of Sciences (PNAS). Now, armed with detailed information about the structure of

Full Post: MRSA’s weak point visualised by scientists



Two clones of highly antibiotic-resistant organism strains, which previously had only been identified in the United States, are now causing serious sickness and death in several Colombian cities including the capital Bogota, say researchers at The University of Texas Medical School at Houston. The study, done in collaboration with Universidad El Bosque in Bogotá, is

Full Post: U.S. ’super bugs’ invading several Colombian cities